1文献来源
Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin＇s lymphoma when high-dose salvage is planned [J]. N Engl J Med, 2011,365（3） ：203-212.
This retrospective analysis compared standard regimen of doxorubicin, bleomycin, vin- blastine, and dacarbazine （ABVD） with the dose-dense ABVD regimen （ABVD-21） in terms of effi- cacy and toxicity. Patients who h...This retrospective analysis compared standard regimen of doxorubicin, bleomycin, vin- blastine, and dacarbazine （ABVD） with the dose-dense ABVD regimen （ABVD-21） in terms of effi- cacy and toxicity. Patients who had early-stage unfavorable or advanced Hodgkin＇s lymphoma （HL） according to German Hodgkin Study Group criteria from March 1999 to February 2011 were ana- lyzed for treatment response, long-term survival and hematological toxicity. There were 85 patients in the ABVD-21 group and 118 patients in the ABVD group respectively. The complete remission rates aider completion of treatment were 92.9% and 90.7% for ABVD-21 and ABVD, respectively. During a median follow-up period of 62 months, no significant difference was found in projected 10-year progression-free survival （PFS） and overall survival （OS） rates （84.7% and 94.1% respectively for ABVD-21; 81.4% and 91.5% for ABVD）. Subgroup analyses showed that ABVD-21 was signifi- cantly better than ABVD for patients with IPS〉3 in terms of PFS and OS rates. Grade 3 to 4 leuko- penia （51.8% vs. 28.8%, P=0.001） and neutropenia （57.6% vs. 39.0%, P=0.009） were more common with ABVD-21. We were led to conclude that dose-dense ABVD did not result in better tumor con- trol and overall survival than did ABVD for early-stage unfavorable HL. However, patients at high risk, for example, with IPS〉3, may benefit from dose-dense ABVD.展开更多
1文献来源
Federico M, Luminari S, Iannitto E, et al.ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin＇s lymphoma： Results from the HD2000 Gruppo Italiano per l...1文献来源
Federico M, Luminari S, Iannitto E, et al.ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin＇s lymphoma： Results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial [J]. J Clin Oncol, 2009,27（5）：805-811.展开更多
BACKGROUND Cutaneous involvement in Hodgkin lymphoma (HL) is a rare finding.Few cases have been reported in literature,most describing paraneoplastic manifestations.Only very few papers have described primary HL skin ...BACKGROUND Cutaneous involvement in Hodgkin lymphoma (HL) is a rare finding.Few cases have been reported in literature,most describing paraneoplastic manifestations.Only very few papers have described primary HL skin infiltration,reporting a wide range of clinical presentations that frequently include ulcers;plaques,nodules and papules have also been noticed.CASE SUMMARY We report the case of a 56-year-old man who presented fever,multiple adenomegalies of neck and axilla and thick serpiginous skin lesions involving bilateral pectoral regions.After an initial diagnostic workup for a suspected active infectious disease,a lymph node biopsy was performed,which showed a neoplastic invasion from a mixed cellularity classical HL.The same histological pattern was described in a cutaneous biopsy of the chest lesions.The other staging procedures performed revealed an advanced disease,with unfavourable clinical prognostic features.The patient was prescribed 6 cycles of ABVD chemotherapy scheme (doxorubicin,bleomycin,vinblastine,dacarbazine),a regiment that requires demonstration of metabolic response achievement at the interim PET/CT scan to confirm continuation or to change therapeutic strategy.CONCLUSION Skin involvement in HL is a rare finding and may represent a challenging clinical presentation due to extremely various types of lesions observed.展开更多
BACKGROUND The outcomes of Hodgkin's lymphoma(HL)in Mexico have not been widely reported.Simplified and affordable treatments have been adopted in middleincome countries.AIM The aim was to evaluate long-used thera...BACKGROUND The outcomes of Hodgkin's lymphoma(HL)in Mexico have not been widely reported.Simplified and affordable treatments have been adopted in middleincome countries.AIM The aim was to evaluate long-used therapies for HL in Mexico in a long-term basis.METHODS In a 34-year time period,88 patients with HL were treated at a single institution in Mexico.Patients were treated with adriamycin bleomycin vinblastine and dacarbazine(ABVD)or mechlorethamine,vincristine,procarbazine,and prednisone(MOPP).Relapsed or refractory patients were given ifosfamide,carboplatin,and etoposide(ICE)followed by autologous or allogeneic stem cell transplants.RESULTS Thirty-seven women and 51 men were included;the median age was 29 years.Patients were followed for a mean of 128 mo.The 310-mo overall survival(OS)was 83%for patients treated with MOPP and 88%for those treated with ABVD.The OS of patients who received autologous stem cell transplantation was 76%(330 mo)vs 93%(402 mo)in those who did not.CONCLUSION HL may be less aggressive in Mexican population than in Caucasians.Combined chemotherapy renders acceptable results,regardless of clinical stage.展开更多
Hodgkin’s lymphoma is a highly treatable malignancy. It has high cure rates yet there are many patients who relapse or are refractory to treatment. Traditionally, treatment has been with conventional chemotherapy;how...Hodgkin’s lymphoma is a highly treatable malignancy. It has high cure rates yet there are many patients who relapse or are refractory to treatment. Traditionally, treatment has been with conventional chemotherapy;however, the development of brentuximab vedotin and immune checkpoint inhibitors has revolutionized the care of Hodgkin’s lymphoma. This is a review of the current advances in the management of Hodgkin’s lymphoma and a review of ongoing clinical trials in the field.展开更多
文摘1文献来源
Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin＇s lymphoma when high-dose salvage is planned [J]. N Engl J Med, 2011,365（3） ：203-212.
文摘This retrospective analysis compared standard regimen of doxorubicin, bleomycin, vin- blastine, and dacarbazine （ABVD） with the dose-dense ABVD regimen （ABVD-21） in terms of effi- cacy and toxicity. Patients who had early-stage unfavorable or advanced Hodgkin＇s lymphoma （HL） according to German Hodgkin Study Group criteria from March 1999 to February 2011 were ana- lyzed for treatment response, long-term survival and hematological toxicity. There were 85 patients in the ABVD-21 group and 118 patients in the ABVD group respectively. The complete remission rates aider completion of treatment were 92.9% and 90.7% for ABVD-21 and ABVD, respectively. During a median follow-up period of 62 months, no significant difference was found in projected 10-year progression-free survival （PFS） and overall survival （OS） rates （84.7% and 94.1% respectively for ABVD-21; 81.4% and 91.5% for ABVD）. Subgroup analyses showed that ABVD-21 was signifi- cantly better than ABVD for patients with IPS〉3 in terms of PFS and OS rates. Grade 3 to 4 leuko- penia （51.8% vs. 28.8%, P=0.001） and neutropenia （57.6% vs. 39.0%, P=0.009） were more common with ABVD-21. We were led to conclude that dose-dense ABVD did not result in better tumor con- trol and overall survival than did ABVD for early-stage unfavorable HL. However, patients at high risk, for example, with IPS〉3, may benefit from dose-dense ABVD.
文摘1文献来源
Federico M, Luminari S, Iannitto E, et al.ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin＇s lymphoma： Results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial [J]. J Clin Oncol, 2009,27（5）：805-811.
文摘BACKGROUND Cutaneous involvement in Hodgkin lymphoma (HL) is a rare finding.Few cases have been reported in literature,most describing paraneoplastic manifestations.Only very few papers have described primary HL skin infiltration,reporting a wide range of clinical presentations that frequently include ulcers;plaques,nodules and papules have also been noticed.CASE SUMMARY We report the case of a 56-year-old man who presented fever,multiple adenomegalies of neck and axilla and thick serpiginous skin lesions involving bilateral pectoral regions.After an initial diagnostic workup for a suspected active infectious disease,a lymph node biopsy was performed,which showed a neoplastic invasion from a mixed cellularity classical HL.The same histological pattern was described in a cutaneous biopsy of the chest lesions.The other staging procedures performed revealed an advanced disease,with unfavourable clinical prognostic features.The patient was prescribed 6 cycles of ABVD chemotherapy scheme (doxorubicin,bleomycin,vinblastine,dacarbazine),a regiment that requires demonstration of metabolic response achievement at the interim PET/CT scan to confirm continuation or to change therapeutic strategy.CONCLUSION Skin involvement in HL is a rare finding and may represent a challenging clinical presentation due to extremely various types of lesions observed.
文摘BACKGROUND The outcomes of Hodgkin's lymphoma(HL)in Mexico have not been widely reported.Simplified and affordable treatments have been adopted in middleincome countries.AIM The aim was to evaluate long-used therapies for HL in Mexico in a long-term basis.METHODS In a 34-year time period,88 patients with HL were treated at a single institution in Mexico.Patients were treated with adriamycin bleomycin vinblastine and dacarbazine(ABVD)or mechlorethamine,vincristine,procarbazine,and prednisone(MOPP).Relapsed or refractory patients were given ifosfamide,carboplatin,and etoposide(ICE)followed by autologous or allogeneic stem cell transplants.RESULTS Thirty-seven women and 51 men were included;the median age was 29 years.Patients were followed for a mean of 128 mo.The 310-mo overall survival(OS)was 83%for patients treated with MOPP and 88%for those treated with ABVD.The OS of patients who received autologous stem cell transplantation was 76%(330 mo)vs 93%(402 mo)in those who did not.CONCLUSION HL may be less aggressive in Mexican population than in Caucasians.Combined chemotherapy renders acceptable results,regardless of clinical stage.
文摘Hodgkin’s lymphoma is a highly treatable malignancy. It has high cure rates yet there are many patients who relapse or are refractory to treatment. Traditionally, treatment has been with conventional chemotherapy;however, the development of brentuximab vedotin and immune checkpoint inhibitors has revolutionized the care of Hodgkin’s lymphoma. This is a review of the current advances in the management of Hodgkin’s lymphoma and a review of ongoing clinical trials in the field.
